Roche licenses Rona Therapeutics’ ALK7 — targeting RNAi obesity drug candidate in deal worth up to $1.16 billion

Roche entered an exclusive worldwide license deal with Rona Therapeutics for an investigational ALK7-targeting RNAi therapy for obesity. Rona will receive up to USD 100 million in upfront and near-term milestone payments. Additional development, regulatory, and commercial milestones could reach USD 1.06 billion, with tiered royalties on global net sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via (Ref. ID: EN69358) on October 13, 2026, and is solely responsible for the information contained therein. (C)